Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

65.95 EUR

0.00 %

14,168 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

0.00 %
+3.61 %
+7.67 %
-4.35 %
-0.98 %
+46.13 %
+21.90 %
+76.24 %
+487.27 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.31B EUR
Turnover
791.17K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
29.10.2025
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2026

Annual report '25

24.3.
2026

General meeting '26

23.4.
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
€180M Nubeqa Milestone Payment and Outlook Update: New Outlook Estimate for 2025, issued 3 December 2025 Revenue is estimated to be €1,820–1,900 million. Operating profit is estimated to be €590–670 million. Previous Outlook Estimate for 2025, issued 28 October 2025 Revenue is estimated...
12/3/2025, 7:18 AM
by Ilkka
22
Orion announced the start of Phase 2 for the ODM-212 molecule. In that project, the target is quite rare cancers, but if successful, ODM-212 could apparently be a valuable addition for many (even more common?) cancers. “…on the potential of the ODM-212 molecule and its mechanism ...
1/8/2026, 11:05 AM
by veronmaksaja
19
It’s quite quiet on the Orion board. The €180M milestone payment didn’t change forecasts, as it was likely already factored in by everyone. The share price is also stagnant, even though the average target price, when the lowest (€46) and highest (€79) forecasts are excluded, is still...
12/19/2025, 2:22 AM
by Tero Vierros
18
From Orion’s own presentations, I have gotten the impression that the dividend will be increased only very moderately for two reasons. Firstly, it ensures a steady increase in the long term. The second reason is, in my opinion, more significant for shareholders: this way, more firepower...
12/19/2025, 4:52 AM
by Level
8
Here are Antti’s comments regarding that recent release. Orion announced on Wednesday that it would receive a EUR 180 million milestone payment based on the sales of the prostate cancer drug Nubeqa. The milestone payment is the last lump sum related to Nubeqa and will be recorded...
12/4/2025, 5:43 AM
by Sijoittaja-alokas
6
Orion’s CEO Liisa Hurme was talking about the company’s business at the Investor 2025 event Inderes Orion sijoituskohteena | Sijoittaja 2025 - Inderes Aika: 28.11.2025 klo 14.16 Orionin toimitusjohtaja Liisa Hurme kertoo yhtiön liiketoiminnasta Sijoittaja 2025 -tapahtumassa.
11/28/2025, 1:40 PM
by Sijoittaja-alokas
5
Siltanen has commented on how ODM-212 is advancing to clinical phase II. Orion announced on Thursday that it has started a clinical phase II study with the cancer drug candidate ODM-212. The candidate’s progression is expected and in line with Orion’s strategy, as the company allocates...
1/9/2026, 6:24 AM
by Sijoittaja-alokas
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.